Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852552 | 1.00 | IL4I1 (0.55) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24852550 | 1.00 | IL4I1 (0.55) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24852551 | 1.00 | IL4I1 (0.55) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24852553 | 1.00 | IL4I1 (0.55) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24852525 | 0.82 | IL4I1 (0.57) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL3717832 | 0.77 | IL4I1 (0.66) | IL4I1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL24852702 | 0.77 | IL4I1 (0.51) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24852522 | 0.75 | IL4I1 (0.61) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24851990 | 0.75 | IL4I1 (0.52) | IL4I1KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL24851784 | 0.73 | IL4I1 (0.60) | IL4I1KDM4ETSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | IL4I1 1/4885KDM4E 878/4885TSHR 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.